ABSTRACT
Introduction
Aminophosphonic acid derivatives constitute a valuable class of biologically active compounds with a great potential for medical and pharmaceutical applications (2) . Aminophosphonates are broadly defined as structural analogues of natural α-aminocarboxylic acids-the "building blocks" of peptides and proteins. By this reason they find increasing use as a tool in the investigation of the cell metabolism and in the development of new drugs against several metabolic disorders (12, 15) . Their close resemblance to the aminocarboxylic acids, the negligible mammalian toxicity and the resistance to proteolytic enzymatic hydrolysis make them extremely important antimetabolites of late (9, 21) . thus, the replacement of proteinogenic amino acid residues in the peptide molecules by aminophosphonate moieties produces peptidomimetics as potential antagonists of the parent peptides (8) . these phosphonopeptides have been shown to serve as antibacterial agents, as well as inhibitors of specific enzymes and receptors (7, 8) . Many of the aminophosphonate derivatives suppress viral replication, inhibit bone resorbtion, delay the progression of bone metastases, exert direct cytostatic effects on a variety of human tumour cells and have found clinical application in the treatment of bone disorders and cancer (4, 6, 17) .
the pharmacological importance and utility of the aminophosphonic acid derivatives have stimulated extensive studies on various aspects of their chemistry, stereochemistry and biological properties (15, 17, 22) . Among the compounds of this group furan-containing aminophosphonates attract particular interest as antitumor agents, because they combine two pharmacophoric fragments in the same molecule-an aminophosphonate moiety and a furan ring.
the synthesis of an aminophosphonate bearing a furan ring, N,N-dimethyl-[N'-methyl(diethoxyphosphonyl)-(2-furyl)]-1,3-diaminopropane and the cytotoxicity of the compound against a panel of leukemic cell lines (HL-60 and its multi drug resistant sub-line HL-60/Dox, LAMA-84 and K-562) has been tested and recently described (10) . the aim of this study is to investigate the in vitro antitumor activity of the furan-containing aminophosphonate, n,ndimethyl-[N'-methyl(diethoxyphosphonyl)-(2-furyl)]-1,3-diaminopropane towards a panel of epithelial human cancer cell lines. in addition, we report the results of the in vitro and in vivo safety testing of the compound.
Materials and Methods
the furan-containing aminophosphonate n,n-dimethyl-[n'-methyl(diethoxyphosphonyl)-(2-furyl)]-1,3-diaminopropane was synthesized through addition of diethyl phosphite to the azomethine bond of the Schiff base n,n-dimethyl-n'-furfurylidene-1,3-diaminopropane using naoc 2 h 5 and cdi 2 as catalysts, as well as without catalyst (10) . the Schiff base n,n-dimethyl-n'-furfurylidene-1,3-diaminopropane was prepared from furfural and n,n-dimethyl-1,3-diaminopropane following a previously described procedure (23) . Diethyl phosphite, furfural and n,n-dimethyl-1,3-diaminopropane were purchased from Fluka Chemie GmbH, Buchs, Switzerland and were purified by vacuum distillation.
In vItro ANTITUMOR ACTIVITY AND SAFETY TESTING OF AN AMINOPHOSPHONATE BEARING A FURAN RING
In vitro investigations the antitumor activity testing was performed on cell cultures from several cell lines (cl) derived from human epithelial tumours using the Mtt test (13) . cell lines from ductal carcinoma of the breast (McF-7 and MDA-MB-231-with low and high metastatic potential, respectively), bladder carcinoma (647-V), hepatocellular carcinoma (hepG2), colon carcinoma (ht-29) and the cl hela-cervical carcinoma, were used in all experiments. The in vitro safety testing was performed according to the latest modification (20) (18) . the cell lines used were routinely grown as monolayers in 75 cm 2 tissue culture flasks (Corning) in high-glucose (4.5‰) Dulbecco's modified minimal essential medium (DMeM), supplemented with 10% fetal calf serum (Sigma) and antibiotics in usual concentrations. cultures were maintained at 37.5°C in a humidified atmosphere and 5% CO 2 .
All experiments were performed in triplicate. The statistical analysis included application of one-way AnoVA followed by Bonferroni's post hoc test. p<0.05 was accepted as the lowest level of statistical significance.
In vivo investigations icR line laboratory mice were treated intraperitoneally (i. p.) with a furan-containing aminophosphonate (10 and 100 mg/ kg). The effect was evaluated 24 and 48 h later. Cytogenetical analysis was conducted according to the protocol described by Preston et al. (16) . All animals were injected with colchicine at a dose of 0.04 mg/g one hour prior the isolation of bone marrow cells. All mice were euthanized by deep anaesthesia with diethyl ether. Bone marrow cells were hypotonized in 0.075M KCl and were fixed in methanol-acetic acid (3:1). Microscopic slides were stained with 5% Giemsa solution (Sigma diagnostic). At least to 50 well-spread metaphases per experimental animal were analysed at random.
For statistical analysis the Student's t-test was applied. Statistical significance was expressed as ***p<0.001, **p<0.01, *p<0.05, p>0.05 -(not significant). Unless otherwise stated eight animals were included per group.
Results and Discussion
The tested furan-containing aminophosphonate exhibited very high antitumor activity in vitro (p<0.001) to the cl derived from human hepatocellular carcinoma (hepG2) in a wide concentration range (from 1 mg/ml to 0.0681 mg/ml and a dilution factor of 6√10=1.47). A similar effect has been observed after application of the test substance on cell cultures from human bladder carcinoma CL 647-V. Significantly lower antiproliferative activity of the aminophosphonate was observed on cells from the cell lines НТ-29 и MDA-MB-231 (p<0.05). the test substance had no antitumor in vitro activity towards the McF-7 and hela cls derived from ductal carcinoma of the breast and from cervical carcinoma, respectively (Fig.   1) . the data from the safety in vitro experiments showed absence of cytotoxicity at all used concentrations, in contrast to the effect of the positive control substance (sodium dodecyl sulfate) (Fig. 2) . the analysis of the cytogenetical data showed that the aminophosphonate applied in two concentrations (10 and 100 mg/kg) exhibited a moderate clastogenic effect-from 2.5 to 5.8% aberrant cells. The chromosomal breaks and fragments occupied a minimum share among all aberrant metaphases. centromer/centromeric fusions prevailed, which leaded to the occurrence of biarmed chromosomes without a visible alteration of the genetic material amount ( Table 1) .
compared to the data obtained for the positive control with Mitomycin C (30.5% cells with aberrations), the genotoxic effects of the furan-containing aminophosphonate were 6 to 12 times lower (Fig. 3) .
Concerning the influence of Ν,Ν-dimethyl-[N'-methyl(diethoxyphosphonyl)-(2-furyl)]-1,3-diaminopropane on the proliferative activity, the values of mitotic index in the bone marrow cell population ranged from 8‰ to 12‰, which is 64.5% of the mitotic activity calculated for the same cellular population from control, vehicle-treated animals. in addition, the value of the same parameter was two fold higher in the animals treated with с Мitomycin C (5.49‰ dividing cells) (Fig. 4) . The genotoxic and antiproliferative effect of the investigated furan-containing aminophosphonate is quite similar to that obtained for previously studied α-aminophosphonic acids (14) and correlate with the absence of in vitro cytotoxicity. hepatocellular carcinoma (hcc) is the most common primary cancer of the liver, accounting for about 75% of all cases. Although HCC is approximately ten times more common in developing countries in east and Southeast Asia and Africa, incidence is rapidly increasing in the United States (1). Rates of hcc in the U.S. have increased by 70% over the past two decades and similar trends have been observed in canada and Western europe (3). in 2008 there were an estimated 694 000 deaths from liver cancer (477 000 in men, 217 000 in women), and because of its high fatality (overall ratio of mortality to incidence of 0.93), liver cancer is the third most common cause of death from cancer worldwide (5).
The major risk factors for HCC are infections with hepatitis B virus (hBV) and hepatitis c virus (hcV) (19) . in addition, cirrhosis of any type, environmental factors, and particularly chemical carcinogens such as aflatoxins, smoking, genetic predisposition (hemochromatosis), and sex hormones may act to promote hepatocarcinogenesis and despite recent advances in the diagnosis and treatment of hcc, its prognosis remains dismal (11).
Conclusions
the described results lead to the conclusion that the furan-containing aminophosphonate Ν,Ν-dimethyl-[N'-methyl(diethoxyphosphonyl)-(2-furyl)]-1,3-diaminopropane could be a good candidate for the development of new anticancer drug for treatment of hepatocellular carcinoma. 
